LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025:
Jefferies Global Healthcare Conference
Date: Wednesday, June 4, 2025
Time: 11:05 a.m. ET / 4:05 p.m. BST
Location: New York, NY
Goldman Sachs 46th Annual Global Healthcare Conference
Date: Monday, June 9, 2025
Time: 2:40 p.m. ET / 7:40 p.m. BST
Location: Miami, FL
A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.
For further information please contact:
| Verona Pharma plc | Tel: +1-844-341-9901 |
| Victoria Stewart, Senior Director of Investor Relations and Communications | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Argot Partners US Investor Enquiries | Tel: +1-212-600-1902 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Ten Bridge Communications International / US Media Enquiries | Tel: +1-781-316-4424 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Wendy Ryan |
About Verona Pharma
Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre® (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
| Last Trade: | US$106.91 |
| Daily Volume: | 0 |
| Market Cap: | US$9.090B |
October 06, 2025 September 24, 2025 September 16, 2025 May 06, 2025 April 29, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
